Program


The program will be updated continuously with more information. 

Day 1 - Thursday, September 22
 08:30-18:00  
    Room
08:30-08:40 Welcome note
Albrecht Stenzinger,University Hospital Heidelberg, Germany
Richard Rosenquist Brandell, Karolinska Institutet, Sweden		 Erling Persson,
Aula Medica
     
08:40-08:45 Welcome note from Journal of Internal Medicine
Karin Ekström Smedby, Karolinska Institutet, Sweden		 Erling Persson,
Aula Medica
     
08:45-09:00 Precision medicine – the future of healthcare
Ole Petter Ottersen, Karolinska Institutet, Sweden		 Erling Persson,
Aula Medica
     
09:00-09:20 New Developments in EU approach towards Personalised Medicine
Alexandru Costescu, European Commission, Research & Innovation, EU		 Erling Persson,
Aula Medica
     
European Precision Medicine Initiatives
Chairs: Albrecht Stenzinger, University Hospital Heidelberg, Germany and Richard Rosenquist Brandell, Karolinska Institutet, Sweden
 		 Room
09:20-09:50 Keynote address: Implementing precision medicine in National Healthcare Services
Sue Hill, National Health Service, England		 Erling Persson,
Aula Medica
     
09:50-10:05 Status on the implementation of the Danish national genome initiative
Birgitte Nybo Jensen, Danish National Genome Center, Denmark		 Erling Persson,
Aula Medica
     
10:05-10:20 The 2025 French Genomics Medicine initiative
Frédérique Nowak, French Genomic Medicine Initiative 2025, France		 Erling Persson,
Aula Medica
     
10:20-10:50 Coffee break Level 3,
Aula Medica
     
10:50-11:05 Implementation of personalized medicine into the German health care system
Nisar Malek, Eberhard Karls University Tübingen, Germany		 Erling Persson,
Aula Medica
     
11:05-11:20 Genomic Medicine Sweden
Anders Edsjö, Region Skåne, Sweden		 Erling Persson,
Aula Medica
     
11:20-11:50 Panel discussion Erling Persson,
Aula Medica
     
Precision Medicine from a policy-maker perspective
Chairs: Anna Lindstrand, Karolinska Institutet, Sweden and Nisar Malek, Eberhard Karls University Tübingen, Germany
 		 Room
11:50-12:05 ICPerMed: International Consortium for Personalised Medicine
Ejner Moltzen, ICPerMed, EU		 Erling Persson,
Aula Medica
     
12:05-12:20 Precision medicine from a policy-maker perspective in Sweden
Jenni Nordborg, The Office for Life Sciences, Sweden		 Erling Persson,
Aula Medica
     
12:20-13:20 Lunch Level 3, 
Aula Medica
     
12:30-13:15 Extra workshop
Precision Medicine Capability at SciLifeLab

12:30-12:35 Precision Medicine Capability at SciLifeLab, Päivi Östling, Scientific Lead for Precision Medicine 

12:35-12:45 Clinical Genomics: The Clinical Genomics Platform and novel technologies for treatment follow up in hematology, Lucia Cavelier, PhD Scientific Director at Clinical Genomics

12:45-12:55 Clinical Proteomics and Immunology: Cellular immunomonitoring for precision medicine in patients with severe inflammatory diseases, AnnaCarin Horne, MD, PhD, Children’s Health unit, Karolinska Institutet, Sweden

12:55-13:05 Spatial Omics: Focus on Spatial Proteomics, Charlotte Stadler, PhD, Platform Co-Director

13:05-13:15 QA		 Level 4,
Aula Medica
     
Ethical/legal challenges for implementing precision medicine
Chairs: Peter Schirmacher, University Hospital Heidelberg, Germany and Katarina Nyström, University of Gothenburg, Sweden
 		 Room
13:20-13:40 Legal considerations
Fruzsina Molnár-Gábor, University of Heidelberg, Germany		 Erling Persson,
Aula Medica
     
13:40-14:00 Ethical considerations
Eva Winkler, University of Heidelberg, Germany (digital)		 Erling Persson,
Aula Medica
     
14:00-14:20 Panel discussion Erling Persson,
Aula Medica
     
Bioinformatics tools and data sharing
Chairs: Valtteri Wirta, SciLifeLab, Karolinska Institutet, Sweden and and Melanie Börries, The University Medical Center Freiburg, Germany
 		 Room
14:20-14:40 PHN and BioMedIT: The Swiss approaches to health data sharing
Katrin Crameri, Swiss Institute of Bioinformatics, Switzerland (digital)		 Erling Persson,
Aula Medica
     
14:40-15:00 Analytical tools for precision oncology
Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, USA (digital)		 Erling Persson,
Aula Medica
     
15:00-15:20 Data sharing with reference to the 1+Million Genome initiative
Ivo Gut, Centro Nacional de Análisis Genómico (CNAG-CRG), Spain		 Erling Persson,
Aula Medica
     
15:20-15:40 Panel discussion Erling Persson,
Aula Medica
     
15:40-16:10 Coffee break Level 3,
Aula Medica
     
16:10-17:00 Short talks on precision medicine
Chairs: Frédérique Nowak, French Genomic Medicine Initiative 2025, France and Anders Edsjö, Region Skåne, Sweden

Implementation of next-generation sequencing in routine diagnostics in (hemato-)oncology at national level in Belgium: report on a real-life pilot, Els Van Valckenborgh, Belgium
Key learnings from building a precision cancer medicine implementation initiative for Norway, Hege Russnes, Norway
Precision Medicine Center Karolinska, Anna Wedell, Sweden
bwHealthCloud: A Data Integration Platform for Personalized Medicine, Aydin Can Polatkan, Germany
A Nordic Network to Promote Precision Medicine Research, Hakon Heimer, Denmark		 Erling Persson,
Aula Medica
     
17:00-18:00 Poster walk
Poster walk leaders: Daniel Kazdal, University of Heidelberg, Germany, Jan Budczies, University of Heidelberg and Valtteri Wirta, SciLifeLab, Karolinska Institutet, Sweden, Anna Lindstrand, Karolinska Institutet, Sweden		 Level 3,
Aula Medica
     
18:00-19:00 Welcome reception and poster mingle Level 3,
Aula Medica
     

Day 2 - Friday, September 23

  
 08:30-17:35  
    Room
Genetic predisposition and patient advocacy
Chairs: Maria Johansson Soller, Karolinska Institutet, Sweden and Peter Schirmacher, University Hospital Heidelberg, Germany
 		  
08:30-08:50 Keynote address: Genetic predisposition to cancer: developments into the next decade
Clare Turnbull, The Institute of Cancer Research, London, UK (digital)		 Erling Persson,
Aula Medica
     
08:50-09:10 Patient advocacy for precision medicine
Natacha Bolaños, European Society for Medical Oncology, Switzerland		 Erling Persson,
Aula Medica
     
Realizing precision medicine clinical trials
Chairs: Anna Martling, Karolinska Institutet, Sweden and Thoas Fioretos, Lund University, Sweden
 		 Room
09:10-09:30 Multi-omics-guided clinical trials in medical oncology
Stefan Fröhling, National Center for Tumor Diseases (NCT) Heidelberg, Germany (digital)		 Erling Persson,
Aula Medica
     
09:30-09:50 Clinical trials in pediatric oncology
Birgit Geoerger, Gustave Roussy, France (digital)		 Erling Persson,
Aula Medica
     
09:50-10:10 Coffee break Level 3, 
Aula Medica
     
10:10-10:30 Precision medicine in overgrowth syndrome
Guillame Canaud, Université de Paris Cité, France		 Erling Persson,
Aula Medica
     
10:30-10:50 Precision medicine for heart diseases - from biomarker discovery to a clinical trial
Jonas Oldgren, Uppsala University, Sweden		 Erling Persson,
Aula Medica
     
10:50-11:10 Panel discussion Erling Persson,
Aula Medica
     
Parallel sessions Room
11:20-12:40 11:20-12:40: Precision medicine in rare diseases
Chairs: Anna Lindstrand, Karolinska Institutet, Sweden and Catherine Boileau, Assistance Publique–Hôpitaux de Paris, France

11:20-11:50: 100,000 Genomes Project. Transforming genomics in healthcare, Mark Caulfield, Queen Mary University of London, UK
11:50-12:10: Precision medicine in rare diseases at Karolinska, Anna Wedell, Karolinska Institutet, Sweden
12:10-12:30: Project TRANSLATE-NAMSE, Daniela Choukair, University Hospital Heidelberg, Germany
12:30:12:40: Panel discussion
 		 Torsten N Wiesel,
BioClinicum
  11:20-12:35: Precision medicine in hematology
Chairs: Thoas Fioretos, Lund University, Sweden and Päivi Östling, SciLifeab, Sweden

11:20-11:40: Functional and data-driven precision medicine in acute myeloid leukemia, Olli Kallioniemi, SciLifeLab, Karolinska Institutet, Sweden
11:40-12:00: Clinical applications of precision medicine in lymphoid malignancies, Anna Schuh, University of Oxford, UK (digital)
12:00-12:20: Implications of the genomic landscape in myelodysplastic syndrome, Elsa Bernard, Memorial Sloan Kettering Cancer Center, USA
12:20-12:35: Panel discussion
 		 Ulf von Euler,
BioClinicum
  11:20-12:30: Precision oncology
Chairs: Albrecht Stenzinger, University Hospital Heidelberg, Germany and Frédérique Nowak, French Genomic Medicine Initiative 2025, France

11:20-11:40: Understanding the relevance of specific mutations for precision treatment, Emile Voest, The Netherlands Cancer Institute, Netherlands
11:40-12:00: Precision medicine clinical trials in cancer, Rodrigo Dienstmann, Instituto Oncoclínicas de Ensino, Brazil (digital)
12:00-12:20: Personal neoantigen-specific vaccines for patients with melanoma and other cancers, Patrick Ott, Dana-Farber Cancer Institute, USA
12:20-12:30: Panel discussion
 		 Erling Persson,
Aula Medica
  11:20-12:35: Precision Medicine in Complex Diseases
Chairs: Åsa Johansson, SciLifeLab, Uppsala University, Sweden and Ole Andreassen, University of Oslo, Norway

11:20-11:40: New precise tools for treating cardiomyopathy, Benjamin Meder, University Hospital Heidelberg, Germany
11:40-12:00: Precision medicine in asthma/allergy, Erik Melén, Karolinska Institutet, Sweden
12:00-12:20: Precision Health in Obesity and Metabolism, Ruth Loos, University of Copenhagen, Denmark
12:20-12:35: Panel discussion		 Level 4,
Aula Medica
     
~12:30-13:00 Presentations by abstract submitters within each parallel session

12:40-13:00: Precision medicine in rare diseases
12:40-12:50: Genome Sequencing is a sensitive first-line test to diagnose individuals with intellectual disability, Marlene Ek, Sweden
12:50-13:00: Germline whole genome sequencing in 105 children with solid tumors: preliminary results from the Swedish Childhood Cancer Predisposition Study, Bianca Tesi, Sweden

12:35-13:00: Precision medicine in hematology
12:35-12:45: Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays, Lucia Cavalier, Sweden
12:45-12:55: Implementation of precision medicine in pediatric oncology in Hungary: The Hungarian Pediatric Oncology Molecular Profiling Programme, Csaba Bödör, Hungary

12:30-13:02: Precision oncology
12:30-12:38: Towards standardization of clinical whole exome sequencing (WES): first results from the German ZPM-WES pilot study, Michael Menzel, Germany
12:38-12:46: Development and Validation of a National Gene Panel (GMS560) for Comprehensive Genomic Profiling of Solid Tumors, Johan Botling, Sweden
12:46-12:54: A comprehensive next-generation sequencing platform to support molecular tumor boards: from sequencing to visualization, Patrick Metzger, Germany
12:54-13:02: Proteomic and functional phenotyping for selection of targeted combination therapies in non-small-cell lunch cancer, Olena Berkovska, Sweden

12:35-12:55: Precision medicine in complex diseases
12:35-12:45: Precision hypertension care, Johan Sundström, Sweden
12:45-12:55: Towards precision medicine for Alzheimer's disease and related disorders, Linus Jönsson, Sweden

  
     
13:00-14:00 Lunch and poster mingle Level 3,
Aula Medica
     
Parallel sessions - continuation Room
14:00-15:00 14:00-15:00: Precision medicine in rare diseases
Chairs: Bianca Tesi, Karolinska Institutet, Sweden and Ann Nordgren, Karolinska Institutet, Gothenburg University, Sweden

14:00-14:25: Molecular pathogenesis in rare diseases, Kym Boycott, University of Ottawa, Canada (digital)
14:25-14:50: Precision phenotyping in rare diseases, Malte Spielmann, Max Planck Institute for Molecular Genetics, Germany
14:50-15:00: Q&A
 		 Torsten N Wiesel,
BioClinicum
  14:00-15:10: Precision medicine in hematology
Chairs: Jean Soulier, Saint-Louis Hospital and University of Paris, France and Karin Ekström Smedby, Karolinska Institutet, Sweden

14:00-14:20: Bispecific antibodies in the treatment of lymphoid malignancies, Martin Hutchings, University of Copenhagen, Rigshospitalet, Denmark
14:20-14:40: Genetic subgroups and treatment in diffuse large B-cell lymphoma, David Scott, BC Cancer Research Institute, Canada (digital)
14:40-15:00: A French network for precision medicine of relapsed leukemias: from genotype to phenotype, Raphael Itzykson, Assistance Publique–Hôpitaux de Paris, France
15:00-15:10: Q&A
 		 Ulf von Euler,
BioClinicum
  14:00-15:10: Precision oncology
Chairs: Anders Edsjö, Region Skåne, Sweden and Albrecht Stenzinger, University Hospital Heidelberg, Germany 

14:00-14:20: Liquid Biopsy: From Discovery to Clinical Application, Catherine Alix-Panabières, Le Centre Hospitalier Universitaire de Montpellier, France
14:20-14:40: RNASeq for cancers of unknown primary, Christophe Le Tourneau, Institut Curie, France
14:40-15:00: Anthology of unusual patterns of somatic mutations in cancer genomes, Ludmil Alexandrov, University of California, USA (digital)
15:00-15:10: Q&A
 		 Erling Persson,
Aula Medica
  13:50-15:00: Precision medicine in complex diseases
Chairs: Bo Jacobsson, University of Gothenburg, Sahlgrenska University Hospital, Sweden and Paul Franks, Lund University, Sweden

13:50-14:10: From populaiton-wide disease trajectories towards decision support in the clinic, Søren Brunak, University of Copenhagen, Denmark
14:10-14:30: Public health translation of results from genome-wide association studies, Andrea Ganna, University of Helsinki, Finland
14:30-14:50: Precision medicine in cardiometabolic disease, Elisabeth Widén, University of Helsinki, Finland
14:50-15:00: Q&A		 Plan 4,
Aula Medica
     
15:00-15:25 Presentations by abstract submitters within each parallel session

15:00-15:25: Precision medicine in rare diseases
15:00-15:08: Genomics – experience, clinical use and educational needs among Swedish health care professionals, Charlotta Ingvoldstad Malmgren, Sweden
15:08-15:16: Analysis of rare damaging germline mutations in 2,135 enriched BRCA-negative breast cancer cases excludes additional high-impact susceptibility gene, Chey Loveday, United Kingdom
15:16-15:24. Evaluating somatic and germline variant calling for clinical production and reduction of false positives with federated data models, Mette Voldby Larsen, Denmark

15:10-15:30: Precision medicine in hematology
15:10-15:20: The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up, Karin E. Smedby, Sweden
15:20-15:30: Evaluation of clinical benefit from a nationwide implementation of precision medicine for all children diagnosed with cancer, Johanna Sandgren, Sweden

15:10-15:26: Precision oncology
15:10-15:18: Strategies for the genomic characterization of solid tumors - four ongoing clinical implementation pilots in Stockholm, Felix Haglund De Flon, Sweden
15:18-15:26: Integrated proteogenomic characterization of metastasizing colorectal cancer: Towards deep proteogenomics for personalized medicine, Matthias Fahrner, Germany

15:00:15:25: Precision medicine in complex diseases
15:00-15:08: The effects of genetic variation in low-density lipoprotein lowering drug targets on rheumatoid arthritis risk using Mendelian randomization, Chenxi Qin, Sweden
15:08-15:16: Status of Genetic testing, Counseling, and Training in Psychiatry in Europe: Opportunities and Pitfalls of the Implementation, Kristiina Tammimies, Sweden
15:16-15:24: Defining a national outbreak surveillance approach for methicillin-resistant Staphylococcus aureus within Genomics Medicine Sweden, Paula Mölling, Sweden

  
     
Precision medicine beyond genomics
Chairs: Albrecht Stenzinger,University Hospital Heidelberg, Germany and Richard Rosenquist Brandell, Karolinska Institutet, Sweden
 		 Room
15:35-15:55 How biology of cancer informs drug development
Thomas Helleday, SciLifeLab, Karolinska Institutet, Sweden		 Erling Persson,
Aula Medica
     
15:55-16:15 Proteogenomics in cancer
Janne Lehtiö, SciLifeLab, Karolinska Institutet, Sweden		 Erling Persson,
Aula Medica
     
16:15-16:35 Methylation profiling for tumor classification
Andreas von Deimling, University of Heidelberg, Germany		 Erling Persson,
Aula Medica
     
16:35-16:55 AI in precision diagnostics
Frederick Klauschen, Ludwig Maximilian University of Munich		 Erling Persson,
Aula Medica
     
16:55-17:15 Innovative precision medicine studies - considerations in trial design, novel agents and technologies
Lillian Siu, University of Toronto, Canada		 Erling Persson,
Aula Medica
     
17:15-17:30 Panel discussion Erling Persson,
Aula Medica
     
17:30-17:35 Summary and closing remarks
Albrecht Stenzinger, University Hospital Heidelberg, Germany and Richard Rosenquist Brandell, Karolinska Institutet, Sweden		 Erling Persson,
Aula Medica